The tussle had centred on the development of mRNA jab technology, which was at the forefront of the fight against Covid-19.

In a report released today, Justin Smith from Bernstein maintained a Buy rating on GlaxoSmithKline, with a price target of £21.70. The company’s shares closed today at p1,373.00. Take advantage of ...

The FTSE 100 began Friday’s session on a positive note, gaining 23 points, reaching 9,124, as investors paid attention to ...

The number of significant shareholder protests has more than doubled so far this year compared with a year ago, with 11 FTSE ...

GlaxoSmithKline Pharmaceuticals' shares fell by 2% in Thursday's morning trade, reflecting a bearish market sentiment. The company is currently trading at Rs 2,680.10 per share.

Detailed price information for Ideaya Biosciences Inc (IDYA-Q) from The Globe and Mail including charting and trades.

Motilal Oswal recommended Neutral rating on GSK Pharma with a target price of Rs 3000 in its research report dated August 02, ...

Pfizer is the closest company to producing a Lyme disease vaccine. Experts are concerned that vaccine skepticism could stand in its way.

Delhi Police have busted a medicine racket making counterfeit life-saving drugs using the names of big pharma companies such ...

The growing healthcare burden posed by hepatocellular carcinoma, the most common subtype of liver cancer, has prompted the ...

GSK (NYSE:GSK) (LON:GSK) said on Monday that the U.S. Food and Drug Administration has accepted its priority review ...